Forex
CYCN Risk Assessment Finds Volatility and Increased Downside Risk
Cyclerion Therapeutics Inc (CYCN) has been assessed for risk in a recent evaluation. The company's current risk assessment score is 1.54, ranking it 285 out of 385 in the Biotechnology & Medical Research industry.
The U.S. Dollar Index is currently neutral, which has a neutral effect on the domestic-focused Biotechnology & Medical Research industry.
CYCN's beta value is 1.80, indicating that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.